Anavex Life Sciences (AVXL) Research & Development (2016 - 2025)
Anavex Life Sciences (AVXL) posted Research & Development of $4.7 million for Q4 2025, down 36.17% sequentially from $7.3 million in Q3 2025, and down 55.43% YoY from $10.4 million in Q4 2024.
Anavex Life Sciences (AVXL) Research & Development (2016 - 2025) Analysis & Trends
Anavex Life Sciences has reported Research & Development for 10 years, with the latest figure at $4.7 million in Q4 2025.
- Quarterly Research & Development fell 55.43% year-over-year to $4.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $31.8 million (down 27.06% YoY) and the FY2025 annual result came in at $37.6 million, down 10.15% from the prior year.
- Research & Development declined to $4.7 million in Q4 2025 per AVXL's latest filing, from $7.3 million in the prior quarter.
- Over five years, Research & Development peaked at $12.1 million in Q4 2022 and troughed at $4.7 million in Q4 2025.
- A 5-year average of $9.5 million and a median of $9.8 million in 2024 frame the typical range for Research & Development.
- The sharpest annual moves came in 2021 and 2025: Research & Development surged 53.53% in 2021, then slumped 55.43% in 2025.
- Over 5 years, Research & Development stood at $8.7 million in 2021, then soared by 39.4% to $12.1 million in 2022, then retreated by 28.04% to $8.7 million in 2023, then gained by 20.29% to $10.4 million in 2024, then plunged by 55.43% to $4.7 million in 2025.
- According to Business Quant data, Research & Development over the past three periods registered $4.7 million, $7.3 million, and $10.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Anavex Life Sciences | 298.40 Mn | 166.65 Mn | - | 4.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.66 Mn |
| Sep 30, 2025 | 7.29 Mn |
| Jun 30, 2025 | 9.96 Mn |
| Mar 31, 2025 | 9.89 Mn |
| Dec 31, 2024 | 10.45 Mn |
| Sep 30, 2024 | 11.61 Mn |
| Jun 30, 2024 | 11.81 Mn |
| Mar 31, 2024 | 9.73 Mn |
| Dec 31, 2023 | 8.68 Mn |
| Sep 30, 2023 | 10.06 Mn |
| Jun 30, 2023 | 10.28 Mn |
| Mar 31, 2023 | 11.31 Mn |
| Dec 31, 2022 | 12.07 Mn |
| Sep 30, 2022 | 11.38 Mn |
| Jun 30, 2022 | 9.27 Mn |
| Mar 31, 2022 | 8.60 Mn |
| Dec 31, 2021 | 8.66 Mn |
| Sep 30, 2021 | 9.37 Mn |
| Jun 30, 2021 | 8.96 Mn |
| Mar 31, 2021 | 6.72 Mn |